A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

To be considered for this study, you must be an adult with multiple myeloma that has either returned or stopped responding to treatment. You should have already tried at least one, but no more than three, different treatments for your myeloma. These previous treatments must have included specific types of drugs: lenalidomide, and another called either a 'proteasome inhibitor' or an 'anti-CD38 monoclonal antibody'. Your general health and how well you can do daily activities will also be assessed, usually by a doctor, and this rating needs to be at a certain level. It's also important that your myeloma has shown signs of getting worse recently, even with your most recent treatment.

There are also some reasons why you might not be able to join the study. If you've previously had a specific type of immune treatment for your myeloma that directly targets something called BCMA on your cancer cells (like certain T-cell therapies), then this study wouldn't be suitable for you. However, if you've had a different type of drug that targets BCMA, called an 'antibody-drug conjugate', that's generally acceptable.

Other reasons for not being able to join include having certain related conditions like plasma cell leukaemia or a specific type of amyloidosis. If your myeloma has spread to your brain or spinal cord, or if you have a history of certain nerve or brain conditions, you would also not be able to participate. The study team will review your full medical history in detail to make sure it's safe and appropriate for you to take part.

If you join this study, you'll receive either linvoseltamab (on its own or with carfilzomib) or one of the standard multiple myeloma treatments. You'll have regular hospital visits for check-ups, blood tests, and to receive your medication. These visits will help the doctors monitor your health, how your body is reacting to the treatment, and how well the treatment is working against your myeloma. The study will also involve collecting blood samples at various times to see how the study drug is handled by your body and to check for any immune reactions. The total length of your participation in the study will depend on how you respond to the treatment and the study's follow-up schedule, which could be for several years.